Today: 21 May 2026
Intel stock price drops 4% into February — what INTC investors are watching next week
31 January 2026
2 mins read

Intel stock price drops 4% into February — what INTC investors are watching next week

New York, Jan 31, 2026, 06:31 EST — Market closed

  • Intel closed Friday down, weighed down by rate concerns and mixed results from tech earnings that continued to drag on chip stocks.
  • The stock remains pressured after last week’s disappointing outlook, as investors zero in on supply issues and margin concerns.
  • U.S. data next week could shift rate expectations — and hit the tech stocks most sensitive to interest rates.

Intel shares dropped 4.4% on Friday, ending the day at $46.47 following a volatile session with prices swinging from $45.97 up to $49.56.

This shift matters because Intel now stands as a major proxy for two clashing debates: the duration of the AI buildout and the impact of rising rates on big-cap tech valuations.

U.S. markets are shut for the weekend, leaving traders to eye Monday for fresh momentum—whether from new macro data or clues on whether Intel’s supply problems are starting to ease.

Wall Street closed lower on Friday, pressured by a hotter-than-expected inflation report and doubts over Donald Trump’s nomination of Kevin Warsh to replace Jerome Powell as Fed chair. Michael Hans of Citizens Wealth said the “markets are calibrating” to the appointment and its implications for policy. Reuters

The day before, the Nasdaq dipped amid doubts over whether huge AI investments will deliver returns fast enough—a concern that’s repeatedly pressured rate-sensitive tech stocks. “There are all sorts of storm clouds in the background,” said John Praveen, managing director and co-CIO at Paleo Leon. Reuters

Intel is still grappling with the fallout from last week’s guidance. The chipmaker projected first-quarter revenue between $11.7 billion and $12.7 billion, with adjusted earnings per share expected to break even—falling short of analyst estimates. Struggles to keep up with demand for server chips powering AI data centers are to blame. “In the short term, I’m disappointed that we are not able to fully meet the demand in our markets,” Lip-Bu Tan told analysts. Reuters

After the report came out, Intel’s execs and analysts flagged supply constraints persisting through Q1, despite factories running full tilt. David Zinsner expects supply to get better in Q2. Meanwhile, TD Cowen analysts suggested the earlier rally was fueled more by optimism than by solid near-term fundamentals.

The competitive landscape remains largely the same. Intel aims to seize AI-driven server demand linked to Nvidia’s leading AI chips, all while holding ground in its PC segment against Advanced Micro Devices.

Investors are focused less on a single quarter’s headline and more on the rhythm: can Intel boost supply without further margin pressure? And will AI data-center expansions keep up the pace needed to offset rising costs?

The downside is straightforward. Should supply bottlenecks drag on beyond forecasts, or if climbing memory prices weigh more heavily on PC demand, Intel’s rebound could stall quickly. That’s especially true in a market that punishes firms sharply when rates climb and expectations run high.

Monday brings fresh U.S. manufacturing data, with the ISM Manufacturing PMI in focus. This survey-based indicator is a go-to for traders looking to gauge factory activity quickly.

Investors are set to focus on the U.S. Bureau of Labor Statistics employment report for January, scheduled for release on Feb. 6 at 8:30 a.m. Eastern. Market watchers will be looking for any clues that might change expectations around interest rates.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut
Previous Story

First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut

Apple stock closes higher after upbeat outlook, but chip squeeze keeps traders cautious
Next Story

Apple stock closes higher after upbeat outlook, but chip squeeze keeps traders cautious

Go toTop